Kevin Outterson is Executive Director and Principal Investigator for CARB-X, a $500M international public-private partnership to accelerate global antibacterial innovation. CARB-X is the world’s largest and most innovative accelerator of antibacterial products. It was established in 2016 to support innovation that addresses the rising threat of drug resistance. Key partners in CARB-X include the US Government (BARDA & NIAID), the Wellcome Trust, the UK Government (GAMRIF, DHSC), the German Federal Ministry of Education and Research, and the Bill & Melinda Gates Foundation.
He also teaches health care law at Boston University, where he co-directs the Health Law Program. Professor Outterson’s research work focuses on the law and economics of antimicrobial resistance. He served as a senior author on many key research reports on antibiotic innovation, including Chatham House, ERG, DRIVE-AB, and the Lancet Commission. Professor Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work. He has testified before Congress, Parliamentary working groups, WHO, and several state legislatures.